Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer

Aurélie Mbeutcha; Shahrokh F Shariat; Malte Rieken; Michael Rink; Evanguelos Xylinas; Christian Seitz; Ilaria Lucca; Romain Mathieu; Morgan Rouprêt; Alberto Briganti; Pierre I Karakiewicz; Tobias Klatte

doi:10.1016/j.urolonc.2016.05.013

Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer

Standard

Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. / Mbeutcha, Aurélie; Shariat, Shahrokh F; Rieken, Malte; Rink, Michael; Xylinas, Evanguelos; Seitz, Christian; Lucca, Ilaria; Mathieu, Romain; Rouprêt, Morgan; Briganti, Alberto; Karakiewicz, Pierre I; Klatte, Tobias.

in: UROL ONCOL-SEMIN ORI, Jahrgang 34, Nr. 11, 16.09.2016, S. 483.e17-483.e24.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mbeutcha, A, Shariat, SF, Rieken, M, Rink, M, Xylinas, E, Seitz, C, Lucca, I, Mathieu, R, Rouprêt, M, Briganti, A, Karakiewicz, PI & Klatte, T 2016, 'Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer', UROL ONCOL-SEMIN ORI, Jg. 34, Nr. 11, S. 483.e17-483.e24. https://doi.org/10.1016/j.urolonc.2016.05.013

APA

Mbeutcha, A., Shariat, S. F., Rieken, M., Rink, M., Xylinas, E., Seitz, C., Lucca, I., Mathieu, R., Rouprêt, M., Briganti, A., Karakiewicz, P. I., & Klatte, T. (2016). Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. UROL ONCOL-SEMIN ORI, 34(11), 483.e17-483.e24. https://doi.org/10.1016/j.urolonc.2016.05.013

Vancouver

Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C et al. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. UROL ONCOL-SEMIN ORI. 2016 Sep 16;34(11):483.e17-483.e24. https://doi.org/10.1016/j.urolonc.2016.05.013

Bibtex

@article{8bb8bf47bc6b46afaf608b8bc30b9937,

title = "Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer",

abstract = "BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein (CRP) are markers of systemic inflammatory response, which have been associated with the prognosis of multiple malignancies, but their relationships with oncologic outcomes of non-muscle-invasive bladder cancer (NMIBC) have not been well studied yet.PATIENTS AND METHODS: We retrospectively reviewed the medical records of 1,117 patients with NMIBC who underwent a transurethral resection of the bladder. Univariable and multivariable competing risk regression models were used to assess the association of preoperative NLR and CRP with disease recurrence and progression to muscle-invasive disease. The median follow-up was 64 months.RESULTS: In total, 360 patients (32.2%) had a high NLR (≥2.5) and 145 (13.0%) had a high CRP (≥5mg/l). On multivariable analyses, a high NLR was associated with both disease recurrence (subhazard ratio [SHR] = 1.27, P = 0.013) and progression (SHR = 1.72, P = 0.007), and high CRP was associated with disease progression (SHR = 1.72, P = 0.031). Adding NLR and CRP to the multivariable model predicting disease progression lead to a relevant change in discrimination (+2.0%). In a subgroup analysis of 300 patients treated with bacillus Calmette-Guerin, both high NLR and high CRP were associated with disease progression (SHR = 2.80, P = 0.026 and SHR = 3.51, P = 0.021, respectively), and NLR was associated with disease recurrence (SHR = 1.46, P = 0.046). There was also an increase in the discrimination of the model predicting progression after bacillus Calmette-Guerin following the inclusion of both markers (+2.4%).CONCLUSION: In patients with NMIBC, markers of systemic inflammation response are associated with disease recurrence and progression. The inclusion of such markers in prognostic models does enhance their accuracy.",

author = "Aur{\'e}lie Mbeutcha and Shariat, {Shahrokh F} and Malte Rieken and Michael Rink and Evanguelos Xylinas and Christian Seitz and Ilaria Lucca and Romain Mathieu and Morgan Roupr{\^e}t and Alberto Briganti and Karakiewicz, {Pierre I} and Tobias Klatte",

note = "Copyright {\textcopyright} 2016. Published by Elsevier Inc.",

year = "2016",

month = sep,

day = "16",

doi = "10.1016/j.urolonc.2016.05.013",

language = "English",

volume = "34",

pages = "483.e17--483.e24",

journal = "UROL ONCOL-SEMIN ORI",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "11",

}

RIS

TY - JOUR

T1 - Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer

AU - Mbeutcha, Aurélie

AU - Shariat, Shahrokh F

AU - Rieken, Malte

AU - Rink, Michael

AU - Xylinas, Evanguelos

AU - Seitz, Christian

AU - Lucca, Ilaria

AU - Mathieu, Romain

AU - Rouprêt, Morgan

AU - Briganti, Alberto

AU - Karakiewicz, Pierre I

AU - Klatte, Tobias

PY - 2016/9/16

Y1 - 2016/9/16

N2 - BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein (CRP) are markers of systemic inflammatory response, which have been associated with the prognosis of multiple malignancies, but their relationships with oncologic outcomes of non-muscle-invasive bladder cancer (NMIBC) have not been well studied yet.PATIENTS AND METHODS: We retrospectively reviewed the medical records of 1,117 patients with NMIBC who underwent a transurethral resection of the bladder. Univariable and multivariable competing risk regression models were used to assess the association of preoperative NLR and CRP with disease recurrence and progression to muscle-invasive disease. The median follow-up was 64 months.RESULTS: In total, 360 patients (32.2%) had a high NLR (≥2.5) and 145 (13.0%) had a high CRP (≥5mg/l). On multivariable analyses, a high NLR was associated with both disease recurrence (subhazard ratio [SHR] = 1.27, P = 0.013) and progression (SHR = 1.72, P = 0.007), and high CRP was associated with disease progression (SHR = 1.72, P = 0.031). Adding NLR and CRP to the multivariable model predicting disease progression lead to a relevant change in discrimination (+2.0%). In a subgroup analysis of 300 patients treated with bacillus Calmette-Guerin, both high NLR and high CRP were associated with disease progression (SHR = 2.80, P = 0.026 and SHR = 3.51, P = 0.021, respectively), and NLR was associated with disease recurrence (SHR = 1.46, P = 0.046). There was also an increase in the discrimination of the model predicting progression after bacillus Calmette-Guerin following the inclusion of both markers (+2.4%).CONCLUSION: In patients with NMIBC, markers of systemic inflammation response are associated with disease recurrence and progression. The inclusion of such markers in prognostic models does enhance their accuracy.

AB - BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein (CRP) are markers of systemic inflammatory response, which have been associated with the prognosis of multiple malignancies, but their relationships with oncologic outcomes of non-muscle-invasive bladder cancer (NMIBC) have not been well studied yet.PATIENTS AND METHODS: We retrospectively reviewed the medical records of 1,117 patients with NMIBC who underwent a transurethral resection of the bladder. Univariable and multivariable competing risk regression models were used to assess the association of preoperative NLR and CRP with disease recurrence and progression to muscle-invasive disease. The median follow-up was 64 months.RESULTS: In total, 360 patients (32.2%) had a high NLR (≥2.5) and 145 (13.0%) had a high CRP (≥5mg/l). On multivariable analyses, a high NLR was associated with both disease recurrence (subhazard ratio [SHR] = 1.27, P = 0.013) and progression (SHR = 1.72, P = 0.007), and high CRP was associated with disease progression (SHR = 1.72, P = 0.031). Adding NLR and CRP to the multivariable model predicting disease progression lead to a relevant change in discrimination (+2.0%). In a subgroup analysis of 300 patients treated with bacillus Calmette-Guerin, both high NLR and high CRP were associated with disease progression (SHR = 2.80, P = 0.026 and SHR = 3.51, P = 0.021, respectively), and NLR was associated with disease recurrence (SHR = 1.46, P = 0.046). There was also an increase in the discrimination of the model predicting progression after bacillus Calmette-Guerin following the inclusion of both markers (+2.4%).CONCLUSION: In patients with NMIBC, markers of systemic inflammation response are associated with disease recurrence and progression. The inclusion of such markers in prognostic models does enhance their accuracy.

U2 - 10.1016/j.urolonc.2016.05.013

DO - 10.1016/j.urolonc.2016.05.013

M3 - SCORING: Journal article

C2 - 27646875

VL - 34

SP - 483.e17-483.e24

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 11

ER -